Liquidia Q3 net loss $23.2M; FDA tentative approval for YUTREPIA; raised $100M

Liquidia Corp

2024-Q3 EPS reported -$1.20 revenue$11,079,000

Net loss of $23.2M ($0.30/diluted share) vs $15.8M loss a year ago; revenue $4.4M from Treprostinil injection promotion.
Cash $204.4M as of Sep 30, 2024, boosted by $67.5M public offering and $32.5M from HCRx RIFA amendment.
FDA granted tentative approval for YUTREPIA (treprostinil inhalation powder) for PAH and PH-ILD; final approval delayed until May 23, 2025.
Supreme Court rejected UTHR appeal on '793 patent; remaining '327 patent trial set for June 2025; Liquidia sued FDA over exclusivity.
Expanded Pharmosa collaboration for L606 to Europe, Japan; $3.5M upfront, up to $157.75M milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.